• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lyra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:11:21 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care
    Get the next $LYRA alert in real time by email
    8-K
    false000132727300013272732025-05-062025-05-06

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 06, 2025

     

     

    Lyra Therapeutics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39273

    84-1700838

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    480 Arsenal Way

     

    Watertown, Massachusetts

     

    02472

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 617 393-4600

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    LYRA

     

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished, and not filed:

    Exhibit

    No.

     

     

    Description

     

     

     

    99.1

     

    Press Release issued on May 6, 2025.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Lyra Therapeutics, Inc.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Jason Cavalier

     

     

     

    Jason Cavalier, Chief Financial Officer

     

     


    Get the next $LYRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LYRA

    DatePrice TargetRatingAnalyst
    5/7/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    5/7/2024$10.00 → $0.50Buy → Hold
    Jefferies
    5/7/2024Buy → Underperform
    BofA Securities
    5/6/2024Outperform → Mkt Perform
    William Blair
    10/6/2023$15.00Buy
    BTIG Research
    8/31/2023$12.00Buy
    H.C. Wainwright
    5/24/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Waksal Harlan bought $74,095 worth of shares (25,000 units at $2.96), increasing direct ownership by 11% to 261,966 units (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/13/23 5:29:27 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Perceptive Advisors Llc sold $182,515 worth of shares (45,875 units at $3.98) (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/13/25 5:07:48 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Large owner Perceptive Advisors Llc sold $344,219 worth of shares (70,390 units at $4.89) (SEC Form 4)

    4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    11/10/25 5:08:46 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by President & CEO Palasis Maria

    4/A - Lyra Therapeutics, Inc. (0001327273) (Issuer)

    10/8/25 4:30:03 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/25/25 4:24:13 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/18/25 4:14:27 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Lyra Therapeutics Inc.

    SCHEDULE 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/13/25 5:05:54 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

    Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

    12/3/24 8:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up

    11/12/24 4:01:58 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

    -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN

    10/15/24 7:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    5/7/24 6:26:06 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously

    5/7/24 6:25:25 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Lyra Therapeutics downgraded by BofA Securities

    BofA Securities downgraded Lyra Therapeutics from Buy to Underperform

    5/7/24 6:25:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 7:48:39 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

    SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    11/14/24 5:49:14 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $LYRA
    Leadership Updates

    Live Leadership Updates

    View All

    Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

    Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

    12/3/24 8:00:00 AM ET
    $LYRA
    Medical/Dental Instruments
    Health Care